CD1d^(hi)CD^(5+)CD19^+调节性B细胞在视神经脊髓炎患者外周血中的数量及意义  

Proportion and significance of CD1d^(hi)CD^(5+)CD19^+ regulatory B cell in peripheral blood of patients with neuromyelitis optica

作　　者：杨芬[1] 黄德晖[2] 程辰[1] 吴卫平[1] 

机构地区：[1]解放军总医院南楼神经内科,北京100853 [2]解放军总医院神经内科,北京100853

出　　处：《细胞与分子免疫学杂志》2015年第3期375-378,共4页Chinese Journal of Cellular and Molecular Immunology

基　　金：十二五国家科技支撑计划课题(2012BAI08B06)

摘　　要：目的检测视神经脊髓炎(NMO)患者外周血中CD1dhiCD5+CD19+调节性B细胞的比例,探讨CD1dhiCD5+CD19+调节性B细胞能否作为NMO和多发性硬化(MS)鉴别诊断的生物标志物。方法采用流式细胞术检测44例NMO患者,38例MS患者和30例健康正常人外周血中CD1dhiCD5+CD19+调节性B细胞的比例。采用间接免疫荧光法检测NMO患者水通道蛋白4抗体(AQP4-Ab)的表达情况。结果 NMO患者外周血中CD1dhiCD5+CD19+调节性B细胞占CD19+B细胞及淋巴细胞的比例较MS患者和健康正常人明显减低,而MS患者与健康正常人比较,差异无统计学意义。AQP4-Ab阳性NMO患者较AQP4-Ab阴性NMO患者CD1dhiCD5+CD19+调节性B细胞占CD19+B细胞及淋巴细胞的比例明显减低。结论外周血中CD1dhiCD5+CD19+调节性B细胞数量是NMO和MS鉴别诊断的一种生物标志物。Objective To detect the proportion of CD1d^hiCD5^＋CD19^＋ regulatory B cells （Bregs） in peripheral blood of the patients with neuromyelitis optica （ NMO）, and explore whether CD1d^hiCD5^＋CD19^＋ Bregs can play a role as a biomarker in the diagnosis of NMO versus multiple sclerosis （MS）. Methods Flow cytometry was performed to detect the proportion of CD1d^hiCD5^＋CD19^＋ Bregs in peripheral blood from 44 cases of NMO, 38 cases of MS, and 30 healthy controls. The serum level of aquaporin-4 antibody （AQP4-Ab） of patients with NMO was detected by indirect immunofluorescence assay. Results The proportion of CD1d^hiCD5^＋CD19^＋ Bregs in CD19^＋ B cells and lymphocytes was significantly lower in NMO group than in MS and control groups; however, there was no significant difference between MS group and control group. The proportion of CD1d^hiCD5^＋CD19^＋ Bregs in CD19^＋ B cells and lymphocytes was lower in AQP4-Ab-positive NMO patients than in AQP4-Ab-negative NMO patients, and the difference was statistically significant. Conclusion CD1d^hiCD5^＋CD19^＋ Bregs may be a biomarker in the differential diagnosis of NMO versus MS.

关 键 词：视神经脊髓炎 调节性B细胞 多发性硬化 水通道蛋白4抗体 

分 类 号：R744.5[医药卫生—神经病学与精神病学] R392.12[医药卫生—临床医学]